𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia—Remarkable activity with room for improvement

✍ Scribed by Ayalew Tefferi; Hagop Kantarjian

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
90 KB
Volume
83
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term response in accelerated-phase
Long-term response in accelerated-phase chronic myelogenous leukemia with protracted splenic irradiation and ?-interferon
✍ Girinsky, T.; Bonomi, M.; Bayle, C. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views

Forming Assay From CD34 + Bone Marrow Cells Serum a BFU-E/10 2 CD34 + cells Control 1 50.2 ± 4.6 Control 2 48.5 ± 14.1 Before chemotherapy 24.4 ± 6.2 b After chemotherapy 50.5 ± 6.5 Values are means ± SD of triplicate cultures. a Control 1; normal AB serum, Control 2; serum from a patient with AILD-

Multicenter prospective trial evaluating
Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter?
✍ Yoshinobu Kanda; Shinichiro Okamoto; Tetsuzo Tauchi; Masahiro Kizaki; Koiti Inok 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

## Abstract Imatinib at a daily dose of 400 mg is the standard treatment for chronic myelogenous leukemia in the chronic phase. However, the feasibility of this dose for small Japanese adults has not been clarified. We prospectively investigated the toxicity and efficacy of this dose in adult Japan

Chronic myelogenous leukemia in nonlymph
Chronic myelogenous leukemia in nonlymphoid blastic phase : Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
✍ Stefano Sacchi; Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Mary Beth Rios 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## BACKGROUND. The prognoses of patients with chronic myelogenous leukemia in blastic phase (CML-BP) are extremely poor. Treatment of patients with nonlymphoid CML-BP is associated with very low response rates, a median survival of 2-3 months, and significant toxicities. The aim of this study was